“It is a fact that for those medicines subject to the reference pricing policy, fair prices are ensured. In other cases, unfortunately, we encounter instances of incorrect pricing policies,” said Mikheil Sarjveladze.

According to Sarjveladze, there is a need to expand reference pricing.

“When we talk about the free circulation of medicines, unfortunately, we may observe certain unfair pricing practices. This requires fair regulation, which means that medicines should be supplied to patients at optimal and fair prices, while at the same time allowing businesses to make a profit.

However, the list of problems does not end here. Unfortunately, we still encounter cases where shortages of medicines are artificially created due to commercial influence. In this regard, active regulation will be necessary, along with preventive measures, to ensure a clear obligation that patients have physical access to all necessary medicines, while maintaining fair pricing.

Such regulation by the state is justified, as it protects patients from excessive and inflated prices. This is entirely logical, and I believe there are no strong or meaningful arguments against it,” said Mikheil Sarjveladze.